Predict your next investment

Corporation
HEALTHCARE | Drug Development
abcellera.com

See what CB Insights has to offer

Business Relationships

10

Service Providers

2

AbCellera Service Providers

2 Service Providers

AbCellera has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Stifel Financial

IPO

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Stifel Financial

Subscribe to see more

Associated Rounds

IPO

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

AbCellera Partners & Customers

10 Partners and customers

AbCellera has 10 strategic partners and customers. AbCellera recently partnered with Salipro Biotech on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/12/2021

Licensor

Salipro Biotech

Sweden

Salipro Biotech Enters Into A Collaboration And License Agreement With AbCellera For Access To The Salipro® Platform For Antibod...

Stockholm / PRNewswire / - Swedish biotech company Salipro Biotech AB today announced that it has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Biotech AB ® Platform , which stabilizes challenging G protein coupled receptor , ion channel , and transporter antigens .

2

9/23/2021

Licensee

Everest Medicines

United States

AbCellera and Everest enter deal to discover antibody therapies

AbCellera and Everest Medicines have signed a multi-year partnership and license agreement to discover therapeutic antibodies for up to ten targets selected by the latter .

2

9/15/2021

Partner

Moderna Therapeutics

United States

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

VANCOUVER , British Columbia -- -- AbCellera Biologics Inc. announced today that it entered into a multi-year , multi-target research collaboration and license agreement with Moderna to leverage AbCellera Biologics Inc. 's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna .

8

8/4/2021

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/6/2021

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/12/2021

9/23/2021

9/15/2021

8/4/2021

5/6/2021

Type

Licensor

Licensee

Partner

Client

Licensee

Business Partner

Salipro Biotech

Everest Medicines

Moderna Therapeutics

Country

Sweden

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Salipro Biotech Enters Into A Collaboration And License Agreement With AbCellera For Access To The Salipro® Platform For Antibod...

Stockholm / PRNewswire / - Swedish biotech company Salipro Biotech AB today announced that it has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Biotech AB ® Platform , which stabilizes challenging G protein coupled receptor , ion channel , and transporter antigens .

AbCellera and Everest enter deal to discover antibody therapies

AbCellera and Everest Medicines have signed a multi-year partnership and license agreement to discover therapeutic antibodies for up to ten targets selected by the latter .

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

VANCOUVER , British Columbia -- -- AbCellera Biologics Inc. announced today that it entered into a multi-year , multi-target research collaboration and license agreement with Moderna to leverage AbCellera Biologics Inc. 's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

8

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.